Analysis of Molecular Cytogenetic Changes in Metastatic Renal Cell Carcinoma in the Setting of Everolimus Treatment: A Pilot Project
-
Published:2014-08
Issue:4
Volume:12
Page:256-261
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
Caldwell Imogen R.,
Oei PaulORCID,
Ng Daniel,
Caudwell Beth,
Fong Peter C.C.,
Broom Reuben J.
Reference24 articles.
1. Metastatic renal cell carcinoma: many treatment options, one patient;Rini;J Clin Oncol,2009
2. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets;Swanton;Genome Med,2010
3. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma;Hudes;N Eng J Med,2007
4. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial;Motzer;Lancet,2008
5. Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC);Motzer;J Clin Oncol,2013
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献